WO2011028344A3 - Interleukin-1 receptor antagonist compositions and methods of making and using same - Google Patents

Interleukin-1 receptor antagonist compositions and methods of making and using same Download PDF

Info

Publication number
WO2011028344A3
WO2011028344A3 PCT/US2010/044040 US2010044040W WO2011028344A3 WO 2011028344 A3 WO2011028344 A3 WO 2011028344A3 US 2010044040 W US2010044040 W US 2010044040W WO 2011028344 A3 WO2011028344 A3 WO 2011028344A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
same
compositions
interleukin
Prior art date
Application number
PCT/US2010/044040
Other languages
French (fr)
Other versions
WO2011028344A2 (en
Inventor
Volker Schellenberger
Joshua Silverman
Willem P. Stemmer
Chia-Wei Wang
Nathan Geething
Benjamin Spink
Wayne To
Jeffrey L. Cleland
Original Assignee
Amunix Operating Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/699,761 external-priority patent/US8673860B2/en
Application filed by Amunix Operating Inc. filed Critical Amunix Operating Inc.
Publication of WO2011028344A2 publication Critical patent/WO2011028344A2/en
Publication of WO2011028344A3 publication Critical patent/WO2011028344A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to compositions comprising IL- 1ra linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of IL- 1 -related diseases, disorders, and conditions.
PCT/US2010/044040 2009-08-25 2010-07-30 Interleukin-1 receptor antagonist compositions and methods of making and using same WO2011028344A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US23683609P 2009-08-25 2009-08-25
US61/236,836 2009-08-25
US24370709P 2009-09-18 2009-09-18
US61/243,707 2009-09-18
US24549009P 2009-09-24 2009-09-24
US61/245,490 2009-09-24
US28095509P 2009-11-10 2009-11-10
US61/280,955 2009-11-10
US28110909P 2009-11-12 2009-11-12
US61/281,109 2009-11-12
US12/699,761 US8673860B2 (en) 2009-02-03 2010-02-03 Extended recombinant polypeptides and compositions comprising same
US12/699,761 2010-02-03

Publications (2)

Publication Number Publication Date
WO2011028344A2 WO2011028344A2 (en) 2011-03-10
WO2011028344A3 true WO2011028344A3 (en) 2011-06-16

Family

ID=43649854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044040 WO2011028344A2 (en) 2009-08-25 2010-07-30 Interleukin-1 receptor antagonist compositions and methods of making and using same

Country Status (1)

Country Link
WO (1) WO2011028344A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4219538A3 (en) 2010-07-29 2023-08-09 Buzzard Pharmaceuticals AB Receptor binding agents
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
LT2804623T (en) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
RS63870B1 (en) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN104519897A (en) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 Procoagulant compounds
ES2770501T3 (en) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Factor VIII complex with XTEN and Von Willebrand factor protein and its uses
HRP20231183T1 (en) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
ES2884813T3 (en) 2013-03-13 2021-12-13 Buzzard Pharmaceuticals AB Chimeric Cytokine Formulations for Ocular Administration
TWI683666B (en) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
EP3004154A4 (en) * 2013-06-05 2017-01-04 Ben Gurion University of The Negev Research and Development Authority IL-1beta-IL-1Ra CHIMERA AND METHODS OF USING THE SAME
EP4368194A3 (en) 2013-06-28 2024-07-31 Bioverativ Therapeutics Inc. Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CU20170038A7 (en) 2014-09-26 2017-10-05 Bayer Pharma AG DERIVATIVES OF ADRENOMEDULIN STABILIZED ESPECIALLY USEFUL IN THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR, EDEMATOS AND / OR INFLAMMATORY DISORDERS
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
TWI744247B (en) 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 Chimeric polypeptide assembly and methods of making and using the same
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190112763A (en) 2017-01-31 2019-10-07 바이오버라티브 테라퓨틱스 인크. Factor IX Fusion Proteins and Methods of Making and Using the Same
KR20200035130A (en) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and uses thereof
US12060424B2 (en) 2017-12-21 2024-08-13 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
CA3090136A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
CN112154153A (en) 2018-03-28 2020-12-29 百时美施贵宝公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
TW202015723A (en) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 Methods of treating hemophilia a
JP7492463B2 (en) 2018-07-03 2024-05-29 ブリストル－マイヤーズ スクイブ カンパニー FGF-21 preparation
MX2021001599A (en) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy.
MX2021004772A (en) 2018-10-29 2021-08-16 Biogen Ma Inc Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport.
EP3891289A2 (en) 2018-12-06 2021-10-13 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
WO2020254197A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
MX2022005676A (en) 2019-11-13 2022-10-27 Amunix Pharmaceuticals Inc Barcoded xten polypeptides and compositions thereof, and methods for making and using the same.
BR112022026127A2 (en) 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc METHODS FOR REMOVING FREE FACTOR VIII FROM LENTIVIRAL VECTOR PREPARATIONS MODIFIED TO EXPRESS SUCH PROTEIN
EP4392566A2 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Baculovirus expression system
JP2024532262A (en) 2021-08-23 2024-09-05 バイオベラティブ セラピューティクス インコーポレイテッド Optimized Factor VIII Gene
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024072801A1 (en) * 2022-09-26 2024-04-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treating a bacterial infection
US20240327538A1 (en) 2023-02-10 2024-10-03 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen and methods for making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
WO2007090584A1 (en) * 2006-02-06 2007-08-16 Csl Behring Gmbh Modified coagulation factor vila with extended half-life
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
WO2007090584A1 (en) * 2006-02-06 2007-08-16 Csl Behring Gmbh Modified coagulation factor vila with extended half-life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VOLKER SCHELLENBERGER ET AL.: "A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner", NATURE BIOTECHNOLOGY, vol. 27, no. 12, 15 November 2009 (2009-11-15), pages 1186 - 1192 *

Also Published As

Publication number Publication date
WO2011028344A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
EP2470670A4 (en) Coagulation factor vii compositions and methods of making and using same
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2011008094A (en) Extended recombinant polypeptides and compositions comprising same.
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
EP3461844A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
WO2007021494A3 (en) Albumin fusion proteins
WO2013055888A3 (en) Recombinant human naglu protein and uses thereof
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
EP3578568A3 (en) Cxcr2 binding polypeptides
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
WO2013074956A3 (en) Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
WO2010088463A3 (en) Polypeptides having expansin activity and polynucleotides encoding same
WO2009038756A3 (en) Long interspersed nuclear element polypeptide compositions and methods of use thereof
WO2012030845A3 (en) Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814129

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10814129

Country of ref document: EP

Kind code of ref document: A2